HEMOGENYX PHARMACEUTICALS - HOPHF STOCK NEWS

Hemogenyx Pharmaceuticals plc (LSE:HEMO) has announced a significant advancement in its CDX bi-specific antibody development for treating relapsed/refractory acute myeloid leukaemia (AML), a subset of acute lymphoblastic leukaemia (ALL), and potentially for conditioning in bone marrow transplantations. The company's scientists have created an improved version of CDX using Lonza's bYlok bispecific pairing technology, which has shown enhanced efficacy in in vitro testing. Additional in vivo studies are currently underway.

CEO Dr. Vladislav Sandler highlighted the potential of this development to improve treatment outcomes for patients with often incurable blood cancers. The advancement could accelerate the product candidate's progress towards clinical trials and potentially attract new industry partners interested in co-developing CDX.

Hemogenyx Pharmaceuticals plc (LSE:HEMO), a clinical-stage biopharmaceutical company, has been invited to present at the 2024 Chemical and Biological Defense Science & Technology (CBD S&T) Conference in Fort Lauderdale, FL, from December 2-5, 2024. The company will showcase its Chimeric Bait Receptor (CBR) platform, an advanced immunotherapy designed to reprogram innate immune cells to combat viral infections and specific types of cancer.

The presentation, titled 'Chimeric Bait Receptor (CBR) for Reprogramming of Myeloid Cells to Target and Eliminate Emerging Viral Infections', will focus on the platform's application in fighting viral threats. Dr. Vladislav Sandler, CEO & Co-Founder, emphasized the opportunity to establish Hemogenyx's position in the biodefense field and engage with experts, potential collaborators, and investors.

Hemogenyx Pharmaceuticals (LSE:HEMO) has announced its participation in the 6th Macrophage-Directed Therapies Summit in Boston, MA, from October 1-3, 2024. The company will present its work on the proprietary Chimeric Bait Receptor (CBR) platform, an advanced immunotherapy designed to program innate immune cells to combat specific cancers and viral threats.

The presentation will focus on using the CBR platform for treating rare cancers. Dr. Vladislav Sandler, CEO & Co-Founder, emphasized the opportunity to establish Hemogenyx's position in myeloid cell therapies and engage with potential collaborators and investors. This event highlights Hemogenyx's commitment to developing innovative treatments for life-threatening diseases, showcasing its state-of-the-art research capabilities in New York City.

Hemogenyx Pharmaceuticals announced the successful passing of all resolutions at its Annual General Meeting held on June 27, 2024. Key resolutions included the adoption of the company's annual accounts, approval of the Directors' Remuneration Report, re-appointment of Sir Marc Feldmann as Director, and re-appointment of PKF Littlejohn LLP as auditors. The voting results showed strong approval from shareholders, with most resolutions receiving over 90% votes in favor. Highlights include a 99.89% approval for the annual accounts and a 99.10% approval for the re-appointment of auditors. The resolutions enable the company to continue its strategic objectives and operational plans effectively.

Hemogenyx Pharmaceuticals has provided an update on its ongoing activities and progress as of June 17, 2024. The company has added a new US medical center to its HEMO-CAR-T clinical trial sites, enhancing its scope and expediting timelines. It is also expanding the HEMO-CAR-T indication to include pediatric AML and ALL. On the Chimeric Bait Receptor (CBR) platform, Hemogenyx is developing multiple CBR constructs for rare cancers and mRNA-based delivery for viral infections. IND-enabling studies for its CDX bispecific antibody are progressing for treating AML and ALL and conditioning in bone marrow transplants. The company is pursuing non-dilutive financing to support these initiatives.

Hemogenyx Pharmaceuticals has announced the posting of its Annual Report and Accounts for the year ending 31 December 2023. The report, along with the Notice of the Annual General Meeting (AGM) and a Form of Proxy, is now available on the company's website. The AGM will take place on 27 June 2024 at 2:00 pm BST at SP Angel Corporate Finance LLP's offices in London. Hemogenyx Pharmaceuticals focuses on developing new medicines and treatments for blood and autoimmune diseases, aiming to expand the curative power of bone marrow transplants.

Shareholders can find more details on the company's investor relations page. The company has its headquarters in London and operates subsidiaries in New York City. The announcement is distributed by RNS, a news service of the London Stock Exchange, and is compliant with regulations established by the Financial Conduct Authority.

Hemogenyx Pharmaceuticals PLC, a biopharmaceutical group focused on blood diseases, announces its final audited results for 2023. Key highlights include the submission of an IND application for HEMO-CAR-T for AML treatment, FDA authorization for Phase I trials, development of CBR antiviral platform, successful fundraising efforts, and a partnership with Prevail InfoWorks Inc. to support clinical trials. The Chairman's statement discusses progress, challenges with FDA standards, fundraising activities, and future plans for HEMO-CAR-T and other pipeline assets.

Hemogenyx Pharmaceuticals plc announces its total issued share capital and voting rights as of March 28, 2024, consisting of 1,341,815,988 ordinary shares. Shareholders can use this figure for notification purposes under the Financial Conduct Authority's rules.

Hemogenyx Pharmaceuticals plc successfully raised US$4.2 million through a Placing of 166,250,000 new ordinary shares at 2 pence per share. The funds will be used for the development of HEMO-CAR-T for the treatment of AML, following the FDA's lifting of the clinical hold on the IND application. The Company aims to progress HEMO-CAR-T to phase 1 clinical trials, with Placing Shares expected to be admitted to trading on the London Stock Exchange Main Market around 6 March 2024.